SGD
LIVE

Serial Number

79193398

Owner

Siegfried Holding AG

Attorney

Jeffrey H. Handelsman

Filing Date

Jun 2, 2016

Add to watchlist:

No watchlists yet
View on USPTO

SGD Trademark

Serial Number: 79193398 • Registration: 5220416

SGD is a trademark filed by Siegfried Holding AG on June 2, 2016. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing). The application is currently registered and active.

Owner Contact Info

Siegfried Holding AG (4 trademarks)

Untere Brühlstrasse 4

Entity Type: 99

Trademark Details

Filing Date

June 2, 2016

Registration Date

June 13, 2017

Published for Opposition

March 28, 2017

Goods & Services

[ Treatment of materials in the nature of spry drying, milling, micronisation, nitration, hydrogenation, phosgenation, halogenation, oxidation, reduction; ] [ Custom manufacture of pharmaceutical products per customer order and in accordance with customer requirements; ] [ custom manufacture of pharmaceutical products as per customer order and in accordance with customer requirements, namely, acetal, aldehyds, alkaloids, esters, ketones, mercaptan, oxalates, acids, vitamins and ingredients used in the manufacture of medicines against cancer ]

[ Pharmaceutical, medical and veterinary preparations for treatment of benign prostate hyperplasia, depression, chronic myeloid leukaemia, glaucoma, ocular hypertension, hypertension, hypotension, asthma, schizophrenia, bipolar disorder, diabetes, mental illness, migraines, cough and cold, blood clots, addiction, skin disorders, central nervous system diseases, urinary tract infection; Dietetic substances and foodstuffs for medical and veterinary use, namely, antidepressant for companion animals, lice treatment; Disinfectants, preparations for destroying vermin; Fungicides, herbicides; Alkaloids for medical use; Analgesics; General anesthetics; ] Chemical preparations for medical use [ ; Chemical preparations for pharmaceutical use for treatment of benign prostate hyperplasia, depression, chronic myeloid leukaemia, glaucoma, ocular hypertension, hypertension, hypotension, asthma, schizophrenia, bipolar disorder, diabetes, mental illness, migraines, cough and cold, formation of blood clots, addiction, skin disorders, central nervous system diseases, urinary tract infection; Chemical preparations for veterinary use, namely, for antidepressant for companion animals, lice treatment; Cellulose esters for pharmaceutical use; Hormones for medical use; Potassium salts for medical use, namely, medicated bath salts; Preparations for acne treatments; Controlled substances, namely, prescription narcotics; Opiates; Pharmaceutical preparations, namely, for treatment of benign prostate hyperplasia, depression, chronic myeloid leukaemia, glaucoma, ocular hypertension, hypertension, hypotension, asthma, schizophrenia, bipolar disorder, diabetes, mental illness, migraines, cough and cold, formation of blood clots, addiction, skin disorders, central nervous system diseases, urinary tract infection; Medicine, namely, sulfonamides; Veterinary preparations for treatment of depression for companion animals, lice treatment; Salts for medical use for treatment of benign prostate hyperplasia, depression, chronic myeloid leukaemia, glaucoma, ocular hypertension, hypertension, hypotension, asthma, schizophrenia, bipolar disorder, diabetes, mental illness, migraines, cough and cold, formation of blood clots, addiction, skin disorders, central nervous system diseases, urinary tract infection; Pharmaceutical alcohols, medicinal alcohols; Medicines for human medicine for treatment of benign prostate hyperplasia, depression, chronic myeloid leukaemia, glaucoma, ocular hypertension, hypertension, hypotension, asthma, schizophrenia, bipolar disorder, diabetes, mental illness, migraines, cough and cold, formation of blood clots, addiction, skin disorders, central nervous system diseases, urinary tract infection; Medicines for veterinary use for treatment of depression for companion animals, lice treatment; Medicines for dental use for local anesthetics; Chemical-pharmaceutical preparations for injections for treatment of benign prostate hyperplasia, depression, chronic myeloid leukaemia, glaucoma, ocular hypertension, hypertension, hypotension, asthma, schizophrenia, bipolar disorder, diabetes, mental illness, migraines, cough and cold, formation of blood clots, addiction, skin disorders, central nervous system diseases, urinary tract infection; Chemical preparations for medical or veterinary use for treatment of benign prostate hyperplasia, depression, chronic myeloid leukaemia, glaucoma, ocular hypertension, hypertension, hypotension, asthma, schizophrenia, bipolar disorder, diabetes, mental illness, migraines, cough and cold, formation of blood clots, addiction, skin disorders, central nervous system diseases, urinary tract infection, treatment of depression for companion animals, lice treatment and veterinary preparations for treatment of benign prostate hyperplasia, depression, chronic myeloid leukaemia, glaucoma, ocular hypertension, hypertension, hypotension, asthma, schizophrenia, bipolar disorder, diabetes, mental illness, migraines, cough and cold, blood clots, addiction, skin disorders, central nervous system diseases, urinary tract infection; Dietetic substances and foodstuffs for medical and veterinary use, namely, antidepressant for companion animals, lice treatment; Disinfectants, preparations for destroying vermin; Fungicides, herbicides; Alkaloids for medical use; Analgesics; General anesthetics; Chemical preparations for medical use; Chemical preparations for pharmaceutical use for treatment of benign prostate hyperplasia, depression, chronic myeloid leukaemia, glaucoma, ocular hypertension, hypertension, hypotension, asthma, schizophrenia, bipolar disorder, diabetes, mental illness, migraines, cough and cold, formation of blood clots, addiction, skin disorders, central nervous system diseases, urinary tract infection; Chemical preparations for veterinary use, namely, for antidepressant for companion animals, lice treatment; Cellulose esters for pharmaceutical use; Hormones for medical use; Potassium salts for medical use, namely, medicated bath salts; Preparations for acne treatments; Controlled substances, namely, prescription narcotics; Opiates; Pharmaceutical preparations, namely, for treatment of benign prostate hyperplasia, depression, chronic myeloid leukaemia, glaucoma, ocular hypertension, hypertension, hypotension, asthma, schizophrenia, bipolar disorder, diabetes, mental illness, migraines, cough and cold, formation of blood clots, addiction, skin disorders, central nervous system diseases, urinary tract infection; Medicine, namely, sulfonamides; Veterinary preparations for treatment of depression for companion animals, lice treatment; Salts for medical use for treatment of benign prostate hyperplasia, depression, chronic myeloid leukaemia, glaucoma, ocular hypertension, hypertension, hypotension, asthma, schizophrenia, bipolar disorder, diabetes, mental illness, migraines, cough and cold, formation of blood clots, addiction, skin disorders, central nervous system diseases, urinary tract infection; Pharmaceutical alcohols, medicinal alcohols; Medicines for human medicines for treatment of benign prostate hyperplasia, depression, chronic myeloid leukaemia, glaucoma, ocular hypertension, hypertension, hypotension, asthma, schizophrenia, bipolar disorder, diabetes, mental illness, migraines, cough and cold, formation of blood clots, addiction, skin disorders, central nervous system diseases, urinary tract infection; Medicines for veterinary use for treatment of depression for companion animals, lice treatment; Medicines for dental use for local anesthetics; Chemical-pharmaceutical preparations for injections, treatment of benign prostate hyperplasia, depression, chronic myeloid leukaemia, glaucoma, ocular hypertension, hypertension, hypotension, asthma, schizophrenia, bipolar disorder, diabetes, mental illness, migraines, cough and cold, formation of blood clots, addiction, skin disorders, central nervous system diseases, urinary tract infection; Chemical preparations for medical or veterinary use for treatment of benign prostate hyperplasia, depression, chronic myeloid leukaemia, glaucoma, ocular hypertension, hypertension, hypotension, asthma, schizophrenia, bipolar disorder, diabetes, mental illness, migraines, cough and cold, formation of blood clots, addiction, skin disorders, central nervous system diseases, urinary tract infection, treatment of depression for companion animals, lice treatment ]

Chemical preparations for use in industry [ , science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins, unprocessed plastics; fertilizing preparations; fire-extinguishing compositions; tempering preparations for use in and soldering ] ; chemical substances for preserving foodstuffs [ ; tanning agents for use in the manufacture of leather, namely, oils for tanning leather; adhesives for use in industry; alkaloids for industrial purposes; Methyl and Acetic acid esters; acids ]

Filing History

INTERNATIONAL REGISTRATION RENEWED
Mar 12, 2026 RNWL
PARTIAL INVALIDATION PROCESSED BY THE IB
Sep 27, 2025 INNP
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
Sep 2, 2025 INNA
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Sep 1, 2025 INPS
INVALIDATION PROCESSED
Sep 1, 2025 INPC
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
May 12, 2025 INPR
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
Sep 11, 2024 NA75
REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.
Sep 11, 2024 C75P
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Apr 9, 2024 APRE
TEAS SECTION 71 & 15 RECEIVED
Aug 3, 2023 ES75
NEW REPRESENTATIVE AT IB RECEIVED
Jun 23, 2023 NREP
NEW REPRESENTATIVE AT IB RECEIVED
Nov 5, 2022 NREP
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Jun 13, 2022 REM3
NEW REPRESENTATIVE AT IB RECEIVED
Jul 30, 2020 NREP
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
May 8, 2019 INNA
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Apr 17, 2019 INPR
AMENDMENT UNDER SECTION 7 - PROCESSED
Aug 17, 2018 A7OK
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jul 9, 2018 APRE
TEAS SECTION 7 REQUEST RECEIVED
Jun 19, 2018 ES7R
FINAL DECISION TRANSACTION PROCESSED BY IB
Oct 28, 2017 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Sep 18, 2017 FICS
FINAL DISPOSITION PROCESSED
Sep 18, 2017 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Sep 13, 2017 FICR
REGISTERED-PRINCIPAL REGISTER
Jun 13, 2017 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 28, 2017 NPUB
PUBLISHED FOR OPPOSITION
Mar 28, 2017 PUBO
NOTIFICATION PROCESSED BY IB
Mar 25, 2017 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 8, 2017 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Mar 8, 2017 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 8, 2017 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Feb 21, 2017 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 9, 2017 CNSA
EXAMINER'S AMENDMENT ENTERED
Feb 7, 2017 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Feb 7, 2017 GNEN
EXAMINERS AMENDMENT E-MAILED
Feb 7, 2017 GNEA
EXAMINERS AMENDMENT -WRITTEN
Feb 7, 2017 CNEA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 26, 2017 GNRN
NON-FINAL ACTION E-MAILED
Jan 26, 2017 GNRT
NON-FINAL ACTION WRITTEN
Jan 26, 2017 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 10, 2016 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 10, 2016 CRFA
ASSIGNED TO LIE
Dec 8, 2016 ALIE
REFUSAL PROCESSED BY IB
Nov 25, 2016 RFNT
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 22, 2016 TROA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Nov 22, 2016 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Nov 22, 2016 REAP
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Nov 9, 2016 RFCS
REFUSAL PROCESSED BY MPU
Nov 9, 2016 RFRR
APPLICATION FILING RECEIPT MAILED
Oct 18, 2016 MAFR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Oct 15, 2016 RFCR
NON-FINAL ACTION WRITTEN
Oct 14, 2016 CNRT
ASSIGNED TO EXAMINER
Oct 12, 2016 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 12, 2016 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 6, 2016 REPR